Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks (Q44774931)
Jump to navigation
Jump to search
scientific article published in September 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks |
scientific article published in September 2006 |
Statements
1 reference
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks (English)
1 reference
Maxime Dougados
1 reference
Stanley B Cohen
1 reference
Maria W Greenwald
1 reference
Richard A Furie
1 reference
Mark C Genovese
1 reference
Edward C Keystone
1 reference
James E Loveless
1 reference
Matthew W Cravets
1 reference
Eva W Hessey
1 reference
Timothy Shaw
1 reference
Mark C Totoritis
1 reference
REFLEX Trial Group
1 reference
1 September 2006
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference